Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Executive Summary
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
You may also be interested in...
Biosimilar Trends: What 2017 May Have In Store
Potential approvals for biosimilar versions of three blockbuster products in the EU and/or the US in 2017, growing prescriber confidence in such products against the backdrop of positive switching studies, and early signs of market consolidation were some of the key trends highlighted at a recent roundtable in Mumbai.
Biosimilar Trends: What 2017 May Have In Store
Potential approvals for biosimilar versions of three blockbuster products in the EU and/or the US in 2017, growing prescriber confidence in such products against the backdrop of positive switching studies, and early signs of market consolidation were some of the key trends highlighted at a recent roundtable in Mumbai.
Shire Exits Biosimilars, Streamlines Oncology Business
Terminating a pair of biosimilar partnerships inherited from Baxalta will better enable Shire to focus on core strengths, CEO Ornskov says. The firm will use Baxalta assets to gradually develop a cancer franchise.